<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539265</url>
  </required_header>
  <id_info>
    <org_study_id>KMD3201</org_study_id>
    <nct_id>NCT01539265</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of Silodosin in Patients With Urinary Calculi</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase II Study of Silodosin in Patients With Urinary Calculi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of silodosin in urinary
      calculi patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous stone passage rate</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to spontaneous stone passage</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic use</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain severity</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment>300</enrollment>
  <condition>Urinary Calculus</condition>
  <arm_group>
    <arm_group_label>silodosin, arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>silodosin, arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>silodosin</intervention_name>
    <arm_group_label>silodosin, arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>silodosin</intervention_name>
    <arm_group_label>silodosin, arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have a unilateral ureteral calculus with ≥ 5 mm and ≤ 10 mm at Week 0.

          -  Patients who are able to visit the site continually as out-patient during the study

        Exclusion Criteria:

          -  Patients who have multiple urethral stones.

          -  Patients who have or have history of a ureteral stricture or other structural passage
             obstruction of the ureter on affected side.

          -  Patients who have been diagnosed with myasthenia gravis, myopathy, spina bifida,
             spinal cord injury, or fibromyalgia syndrome.

          -  Patients who have a clinically significant hepatic or renal disorder.

          -  Patients with postural hypotension or with a history of postural hypotension.

          -  Patients with a history of sever drug allergy, or patients with a history of
             hypersensitivity to silodosin.

          -  Patients who are pregnant, nursing, or desire pregnancy during the study period, or
             patients who cannot strictly comply with a physician's contraception directions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuro Takei</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Development Department, Kissei pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan</name>
      <address>
        <city>Tokyo and Other Japanese City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary calculus</keyword>
  <keyword>ureteral stones</keyword>
  <keyword>medical expulsive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silodosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

